Brandenburg Kapital - News about 4TEEN4 Pharmaceuticals GmbH
4TEEN4 Receives Accelerated Approval Designation in the United States
Potsdam, Hennigsdorf - July 2026 - The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Brandenburg Kapital's portfolio company 4TEEN4 Pharmaceuticals GmbH (4TEEN4) for its drug candidate for the treatment of cardiogenic shock.
The Fast Track program is intended to accelerate the regulatory review and approval process for innovative therapies addressing serious conditions with significant unmet medical needs.
The Hennigsdorf-based 4TEEN4 is currently evaluating its drug candidate, Invobenitug, in a Phase Ib/IIa clinical trial involving patients across several european countries. The company views the Fast Track Designation as another important milestone in the development of the therapy, which pursues a novel approach by targeting a molecular driver of physiological shock. The significance of this innovative drug candidate is now further underscored by the FDA's decision.
Brandenburg Kapital has been an investor and shareholder in 4TEEN4 since 2019 and congratulates the team on this major achievement.
Click here for the press release:
For more information, visit:
www.brandenburg-kapital.de , 4TEEN4 Pharmaceuticals GmbH
About 4TEEN4 Pharmaceuticals GmbH
4TEEN4's mission is to reverse life-threatening shock and restore organ function with Invobenitug (previously Procizumab). This highly specific, first-in-class antibody blocks circulating DPP3, the key pathological driver of mortality in shock. Based on highly encouraging results across preclinical models and initial use in patients, Invobenitug is now in a Phase Ib/IIa study evaluating its potential as a treatment for shock caused by acute cardiovascular and septic events. By targeting the root cause, 4TEEN4 aims to move shock treatment beyond supportive care and improve survival in critically ill patients.